Interpace Biosciences, Inc. (IDXG)
OTCMKTS
· Delayed Price · Currency is USD
0.6700
+0.0100 (5.51%)
May 2, 2025, 4:00 PM EDT
Interpace Biosciences Employees
Interpace Biosciences had 111 employees as of December 31, 2024. The number of employees increased by 3 or 2.78% compared to the previous year.
Employees
111
Change (1Y)
3
Growth (1Y)
2.78%
Revenue / Employee
$422,757
Profits / Employee
$56,198
Market Cap
3.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Interpace Biosciences News
- 11 days ago - Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 3 months ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results - GlobeNewsWire
- 3 months ago - PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan - GlobeNewsWire
- 4 months ago - Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 6 months ago - Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results - GlobeNewsWire
- 7 months ago - Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq - GlobeNewsWire
- 9 months ago - Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results - GlobeNewsWire
- 10 months ago - Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts - GlobeNewsWire